Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months)

Lilly

Status and phase: Completed; Phase 4

Conditions: ADHD

Treatments: Drug: placebo; Drug: Atomoxetine Hydrochloride

Study type: Interventional

Funder types: Industry

Identifiers

NCT00190736

B4Z-US-LYCU

9040

Details and patient eligibility

About

A study to compare the effect of once-daily atomoxetine versus placebo in treating symptoms of ADHD in adults for up to 6 months.

Sex: All

Ages: 18 to 54 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male and Female patients with ADHD ages 18-54.
• Patient must have ADHD symptoms that cause problem(s) in the home setting.

Exclusion criteria

• Have failed to respond to an adequate trial of treatment with an ADHD stimulant medication, bupropion, or other nonstimulant medication.
• Are taking any antipsychotic medication or mood stabilizers within 8 weeks of Visit 1

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind